Abstract Submission

50th EDEG meeting

25-27 April 2015

Chantilly, France.

Deadline for abstracts: 12 January 2015

         edeg@swansea.ac.uk

The theme of the 2015 meeting is Pharmacoepidemiology, and abstracts on this theme will be preferentially selected for oral presentation.  We will preferentially select more junior researchers for oral presentations.

Poster presentations will include a 5 minute presentation in front of the poster, to describe the principal results. 

A structured abstract in Arial 10 font, with single line spacing should have the following headings:

1. Title of abstract in bold and CAPITALS font 

2. Authors (first and last names) in bold font, with the name of the presenting author underlined

3. Author affiliations / institutions as numbered items

4. Abstract text to include Background, Methods, Results, and Conclusions.

Leave a one line space between each of these headings, and single line spacing for the abstract. The entire abstract should have a maximum of 350 words (excluding the authors names and their institutes) and tables or black and white diagrams may be used. The abstract must be on one A4 page with 2.5 cm margins.

Please see below for an example, and follow the formatting of this example.

Only one abstract may be submitted per presenting author. If the author is not able to attend, the abstract should be withdrawn.

Please submit abstracts before the 12^th January to edeg@swansea.ac.uk.

Abstract submission and registration will be dealt with by Liz Irvine. If you have any query please contact e.m.irvine@swansea.ac.uk or beverley.balkau@inserm.fr.

Information about the authors should appear on a second page, in the format below, and as shown in the example.

Information about authors and the abstract

Title: repliche orologi italia

Abstract Author:    

Presenting Author:                       

E-mail of presenting author:      

Institute and address of presenting author:

Telephone and fax numbers of presenting author:

Presentation Preferred: (select)                           

Oral

            Poster

Theme of presentation: (select the appropriate theme)

Pharmacoepidemiology

            Type 1 diabetes

            Type 2 diabetes risk factors

            Type 2 diabetes complications or mortality studies

            Other

I am a younger researcher: (cross out if this is not the case)

MSc Student    

            PhD Student

            Post Doctorate researcher

            I have published  ___________  research papers

As presenting author I agree to my name, institution and e-mail address being included in the EDEG 2105 abstract book.

Cross out this sentence – if you do not agree.

Example of an abstract and information about the presentation and authors

 fausse sacoche

RELATIONSHIP OF HBA_1C WITH BODY WEIGHT CHANGE OVER 4 YEARS FROM STARTING INSULIN THERAPY IN TYPE 2 DIABETES – THE CREDIT STUDY

Nick Freemantle¹, Beverley Balkau², Francoise Calvi-Gries³, Valerie Pilorget⁴, Maya Vincent⁴, Philip Home⁵

¹Department of Primary Care and Population Health, University College London, UK; ²CESP INSERM, U1018 & University Paris Sud 11, UMRS 1018, Villejuif, France; ³AtlanStat, Rezé, France; ⁴Sanofi, Paris, France; ⁵Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

Background:  Insulin treatment is often delayed in type 2 diabetes due to fear of weight gain and its consequences on glycaemic control. Clinical trials provide some insights, but have limited generalizability due to participant selection and treatments used.  We examine the relationship between change in body weight and HbA_1c after 4 years of insulin therapy in routine clinical practice.

Material and methods:  CREDIT (Cardiovascular Risk Evaluation in people with Type 2 Diabetes on Insulin Therapy) was a non-interventional study of people with type 2 diabetes beginning insulin therapy in Europe, North America and Asia. Physicians were free to choose and adapt treatments, according to usual practice; data were collected from physician records. Univariate and multivariable analyses describe relations between change in body weight and HbA_1c over 4 years.

Results:  Determinants of 4-year HbA_1c were studied in 1973 people with type 2 diabetes after starting insulin; 47% were men, baseline mean age 61 ± 10 (SD) years, BMI 29.2 ± 6.1 kg/m², 10 ± 8 yr of diabetes, HbA_1c 9.5 ± 1.9 % (80 ± 21 mmol/mol), 69% continuing oral glucose-lowering therapies.  In the first year, HbA_1c declined and then remained stable (Figure), with a decrease at year 4 of

–2.0 ± 2.1 % (–22 ± 23 mmol/mol).  Body weight increased an average of 1.9 ± 4.7 kg in the first year and by 2.6 ± 7.4 kg over 4 years. Daily insulin dose increased by 0.15 ± 0.23 U/kg in the first year, and by 0.27 ± 0.31 U/kg over the 4 years. The 4-year change in weight was predictive of HbA_1c at year 4 (p<0.0001), but with a small effect size: a weight gain of 2.6 kg was associated with a 0.005%-unit (0.05 mmol/mol) higher HbA_1c at year 4. Taking other variables into consideration, weight change remained predictive of HbA_1c at year 4 (p<0.04).

Conclusions:  After 4 years of insulin treatment in people with type 2 diabetes, weight gain was associated with minimally higher HbA1c at year 4. These results should allay fears of weight gain having a strong impact on glycaemic control.

Study supported by Sanofi

(Graph)